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A Sudden Increase in Factor VIII Inhibitor Development in Multitransfused
Hemophilia A Patients in The Netherlands
By F R Rosendaal, H K. Nieuwenhuis, H M. van den Berg, H Heijboer, E P Mauser-Bunschoten, J. van der Meer,
C Smit, P F W Strengers, E Briet, and the Dutch Hemophilia Study Group
The development of antibodies to factor VIII (Inhibitors) in
response to clotting-factor concentrates administration in
hemophilia is common during the first few years of treat-
ment but rare in multitransfused patients. We have inves-
tigated the possible association of a recently introduced
factor VIII concentrate (Factor VIII CPS-P) in The Nether-
lands with the occurrence of Inhibitors. To this effect, we
conducted two studies. First, we performed a national
multicenter study in which clinical Information and Inhibitor
test results were obtained for 447 hemophilia A patients
over the period 1988 through 1991. Secondly, for a baseline
comparison we estimated the frequency of Inhibitor de-
velopment in a closely followed cohort of 144 patients, from
1984 through 1989. Before the introduction of Factor VIII
CPS-P, the incidence of new Inhibitors was 4.4/1,000 pa-
tient-years in the national study from March 1988 through
May 1990, and 3.9/1,000 patient-years in the cohort fol-
lowed from 1984 through 1989. These figures are similar
to the incidence of new Inhibitors that was found in a large
cohort of patients in the United States followed in the
1970s. In the period that the new concentrate Factor VIII
CPS-P was on the market, from June 1990 through No-
vember 1991, 11 clinically relevant Inhibitors were de-
tected, which yielded an incidence over this interval of 20.1 /
1,000 patient-years, a 4.5-fold increase compared with the
previous interval (COS: 1.4 to 14.3). Nine of these 11 pa-
tients had in their lifetime received over 250 inf usions with
factor VIII preparations, whereas all of the Inhibitors de-
tected in the previous time interval, and all of the 24 Inhibitor
patients described in the US study, had received less than
250 infusions in their lifetime. All patients who developed
Inhibitors after June 1990 had been exposed to Factor VIII
CPS-P, whereas only 75% of the patients who did not de-
velop an Inhibitor had been exposed to this product. In a
prospective extension of the study, with a second Inhibitor
measurement after 3 months, we found that one additional
inhibitor had developed during 52.5 patient-years of Factor
VIII CPS-P use. In conclusion, there has been a sudden
increase in the frequency of inhibitor patients, for a large
part among multitransfused patients. It seems more than
likely that this increase is associated with the introduction
of a new factor VIII concentrate in The Netherlands. To
avoid future and possibly (arger epidemics of inhibitor de-
velopment, physicians who treat hemophilia patients should
perform inhibitor tests at regulär intervals, especially when
their patients change from one clotting factor preparation
to another.
© 1993 by The American Society of Hematology.
HEMOPHILIA A is a sex-hnked hereditary bleedmg dis-order caused by a complete or partial deficiency of
clotting factor VIII. In severe hemophilia (complete defi-
ciency) bleedmg occurs spontaneously, notably m joints and
soft tissue In milder forms (partial deficiency) bleedmg usu-
ally only results from trauma or surgery The disease pre-
dommantly affects men (approximately 20/100,000 live male
births1), although in rare cases female carners may prove
symptomatic. Repeated bleeding in jomts causes arthropathy
that may lead to disabihty, whereas intracramal bleeding,
mtestmal tract bleeding, and traumatic bleedmg may be fatal.2
In 1964 Pool et al3 reported a simple method to purify
factor VIII by cryoprecipitaüon from human plasma. This
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marked the begmmng ofthe era of modern hemophilia treat-
ment, in which the missmg clotting factor is intravenously
admmistered to either stop or prevent bleeding The avail-
abihty of adequate replacement therapy has improved the
life expectancy for severe hemophilia from less than 30 years
before 1960 to a near-normal life span,4 5 with accompanymg
improvements in physical condition and social circum-
stances.6 These improvements have been set back by trans-
mission of viruses through donated blood, especially hepatitis
viruses and the human immunodeficiency virus (HIV)7~9
Another major comphcation of hemophilia A treatment is
the development of antibodies to factor VIII m some patients,
the so-called mhibitors.10 13 Inhibitors have been estimated
to occur m 20% of all patients with severe hemophilia A,14"17
although one recent study found an even larger risk of 52%
in severe hemophilia A 18 Inhibitor formation greatly com-
phcates therapy, because bleeding can no longer be effectively
treated or prevented by factor VIII administration. This im-
phes that inhibitor patients cannot fully enjoy the benefits of
Substitution therapy, and have a mortality that is higher than
that of patients without mhibitors.5
Inhibitors usually develop in the early phase of treatment
with clotting-factor preparations, in many cases after only a
few infusions Once more than 100 to 250 infusions have
been admmistered, inhibitor development appears to be
rare.13·19 20 Therefore, mhibitors are often detected at a young
age, although occasionally transient mhibitors are detected
m older multitransfused patients, usually without clinical se-
quelae 19 In a cohort of 1,306 hemophilia A patients of a US
multicenter follow-up study on inhibitor development, m-
hibitors were detected m 31 patients, which yielded an in-
cidence of 8/1,000 person-years.19 Twenty-four of these m-
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hibitors were persistent (type A), whereas m seven patients
transient mhibitors were found (type B) No Inhibitors were
found in patients who had received m their hfetime more
than 250 mfusions of factor VIII
The developments smce the 1960s have led to the avail-
ability of more and more concentrated factor VIII products,
factor VIII concentrates purified by monoclonal anübodies
(MoAbs), and most recently, concentrates pioduced by re-
combmant DNA techniques 21 22 Concerns have been raised
that these ultra-pure concentrates might entail an higher nsk
of mhibitor development compared with conventional con-
centrates 23 25 Because of the lack of comparable data, this
issue remams unsettled at present, but it seems clear that the
newest developments have at least not dimmished the prob-
lem of mhibitor formation 2I 25 28
In 1990, a new plasma-denved pasteunzed factor VIII
concentrate (Factor VIII CPS-P) became licensed for he-
mophilia A treatment m The Netherlands, and was subse-
quently used to treat the majonty of Dutch hemophilia A
patients In 1991, we became aware of four patients who had
developed mhibitors accompamed with severe climcal prob-
lems This was considered unusual, because these patients
had received numerous mfusions m their hfetime with several
clotting factor preparations In addition, five recently dis-
covered mhibitor patients were simultaneously reported by
the hemophilia center in Leuven, Belgium, among 109 pa-
tients who were treated with Factor VIII CPS-P m a random-
ized tnal 29 Several of these patients had received replacement
therapy for many years before the occurrence of the mhibitor
These reports of mhibitor patients were followed by additional
reports from vanous hemophilia centers in The Netherlands
Because mhibitor development m multitransfused patients
is rare, and an association with the mtroduction of a new
factor VIII concentrate seemed relevant, we started a national
study on the occurrence of mhibitors In addition, we have
estimated retrospectively the mcidence of mhibitors in a co-
hort of Dutch patients to obtam a baseline estimate for com-
panson and to avoid conclusions based solely on compansons
with experiences from other countnes
MATERIALS AND METHODS
Hemophilia treatment in The Netherland<i In The Netherlands,
with a total population of almost 15 milhon mhabitants, there are
approximately 1,100 patients with hemophilia A Sixty percent of
these, ιέ, 600 to 700 patients, have severe (<1% factor VIII C) or
moderately-severe (1% to 5% factor VIII C) hemophilia A and receive
mfusions with clotting factor preparations at more or less frequent
intervals' 6 The total national consumption of factor VIII for the
treatment of hemophilia A is over 45 milhon IU per year30 Until
1988, Substitution treatment m hemophilia A consisted of small-
pool dry-heat-treated cryoprecipitate and dry-heat-treated inter-
mediate-punty concentrate, produced by regional blood banks and
the Central Laboratory of The Netherlands Red Cross Blood Trans-
fusion Service (CLB) These factor VIII products, produced from
plasma of Dutch donors, covered most of the factor VIII need, whereas
imported concentrates held a market share of 10% or less In March
1988, the CLB mtroduced a factor VIII concentrate to replace the
previous concentrate Factor VIIICPS This concentrate was produced
by a controlled-pore sihca (CPS) adsorption techmque developed m
New Zealand31 In May 1990, pasteunzation m the fluid phase in
the presence of a mixture of stabilizers replaced the dry-heat treatment
äs the method for virus mactivation,32 and the product became known
äs Factor VIII CPS-P This concentrate contamed about l U of factor
VHI/mg protem Residual protein contammation consisted of fi-
brmogen, fibronectin, albumm, IgG gammaglobulms, and a2-rnac~
roglobulm Factor VIII CPS-P became the almost solely used product
for hemophilia A treatment m The Netherlands, because cryopre-
cipitate could not be pasteunzed and was therefore not considered
hepatitis C safe Consequently, in June 1991 cryoprecipitate lost its
hcence for the treatment of hemophilia A m The Netherlands Pas-
teunzed Factor VIII CPS has, to our knowledge, only been used m
The Netherlands and in Belgium
National study on recently developed Inhibitors We asked the
Dutch hemophilia treatment centers to supply us with climcal m-
formation and mhibitor lest results of all their patients with hemo-
philia A who had been treated with human coagulation preparations
smce January l , 1991 Climcal data mcluded general Information
(date of birth, seventy of hemophiha), the presence of overt climcal
signs of an mhibitor, such äs changes in type of bleedmg or the re-
sponse to treatment of bleedmg (in which case an mhibitor was clas-
sified äs clmically relevant), product (brand name and transfusion
frequency), and mhibitor Status (results of previous mhibitor tests,
date of first detection) For product use, we asked Information on
two time penods March 1988 through May 1990 (penod 1), and
June 1990 through November 1991 (penod 2), m which respective
penods Factor VIII CPS and Factor VIII CPS-P had been on the
market In all patients a Bethesda mhibitor test was performed for
this national study by the classical method äs descnbed by Kasper
et al 33
In case of recently developed mhibitors, ic, after March 1988, we
obtamed additional Information on the mhibitor titres, (cumulative)
exposure days to factor VIII products before the mhibitor develop-
ment, whether the mhibitor was detected because of climcal suspicion
or routme mvestigations (or this study), whether the mhibitor had
led to climcal Symptoms, and whether the mhibitor had been persistent
or transient The mhibitor tests of these patients were repeated and
confirmed in one reference laboratory
We extended the study prospectively, by performing a second m-
hibitor test after 3 months m the non-mhibitor patients who had
been exposed to factor VIII products dunng the interval
It has been shown that when a group of patients are tested on
mhibitors, some patients will show low-ütered mhibitors without any
Symptoms These mhibitors, that have been called type B,19 may
reflect an mnocuous transient phenomenon, or a false-positive lab-
oratory result In contrast, clmically relevant Inhibitors (type A) are
repeatedly detectable and usually have a higher titer " In case of a
possible type B mhibitor, le, a low-titer mhibitor without climcal
Symptoms, we repeated the mhibitor test after several weeks In our
prevalence and mcidence calculations we have restncted ourselves
to clmically relevant mhibitors, le, mhibitors that led to a decreased
climcal response to treatment of bleedmgs
We analyzed the data separately for the two time penods that
marked the mtroduction of Factor VIII CPS and the subsequent
replacement by Factor VIII CPS-P Incidence rates were calculated
by the patient-year method, by considermg the patients reported on
in the present äs a cohort followed from March 1988 to the present
Although this might lead to distortion because patients who died or
were lost to follow-up between March 1988 and the present would
be missmg, we feit that the time frame was so short äs to mmimize
this distortion Incidence rates were calculated äs the ratio of the
number of events over the patient-years of observation Confidence
intervals (CI95) for the mcidence rates were calculated under the
assumption of a Poisson distnbution, and for prevalence figures by
the normal approximation of the binomial distnbution Counts were
compared by Fisher's exact tests and by chi-squared tests
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Table 1 Patient Characteristics in the National Study
and the Cohort 1984 Through 1989
Seventy of hemophilia
Severe(<1%FVIIIC)
Moderately-severe (1%-5% FVIII C)
Mild (5%-40% FVIII C)
Age distnbution (yrs)
0-5
6-10
11-15
16+
Mean age (SD)
Age ränge
National Study
(n - 447)
n(%)
292 (65)
74(17)
81 (18)
33(7)
36(8)
37(8)
341 (76)
Years
30 (17)
1-83
Cohort
1984 1989
(n = 144)
n(%)
99 (69)
26(18)
19 (13)
18 (13)
15 (10)
15 (10)
96 (67)
Years
21 (13)
0-60
Retrospective cohort study on Inhibitor development (cohort 1984
through 1989) We collected data on Inhibitor measurements of all
240 patients with hemophilia A registered at the national heraophiha
center Van Creveld Clmic and the University Hospital Utrecht, who
were identified through the Computer flies on Inhibitor tests Excluded
were patients who were known to have (or have had) an mhibitor at
the time of entry to the study (n = 23) or who had not been exposed
to factor VIII durmg the study penod (n = 73) The observation time
for the remaming 144 patients was defined äs the time from the first
(negative) mhibitor test after January l, 1984 until either the last
negative test before January l, 1990 or the first positive test (before
January l, 1990) A level exceeding l 0 BU/mL was considered äs a
positive mhibitor test
RESULTS
National study on recently developed mhibitors Thirty-
four centers reported 475 hemophilia A patients for our study
and had performed mhibitor tests in 447 patients. This im-
plied that we obtamed data on two thirds of all patients with
severe and moderately severe hemophilia A m The Nether-
lands. General charactenstics of these patients are shown in
Table l
A total of 50 patients were reported m whom an mhibitor
was present or had ever been present in the past; these were
considered "ever" mhibitors In 33 patients the mhibitor was
first detected before the begmnmg of our study interval m
1988; in 17 patients a new mhibitor was detected recently,
le, within the time frame of the study from March 1988
through November 1991 In 29 of these 50 "ever" mhibitor
patients the mhibitor was still present at the measurement
m 1991, and these 29 patients were considered "current"
mhibitors.
Ofthe 17 mhibitors detected m or after 1988, 15 had chn-
ical Symptoms and were classified äs type A mhibitors Four
of these were first discovered m penod I (March 1988 through
May 1990), and 11 m penod II (June 1990 through November
1991) (see Table 2). The maximum titres varied from 2 to
457 BU/mL All but l of these 15 type A mhibitors were
detected because of a clmical suspicion. Two patients (of these
17), who were both detected in November 1991, had no
Symptoms and had low mhibitor titers (l .4 and l .5 BU/mL);
these were both classified äs type B mhibitors. In l of these,
the mhibitor was no longer detectable after several weeks,
and m l it remamed of a low titer (l 2 BU/mL) without any
clmical Symptoms.
Table 2. Type A Inhibitor Patients in the National Study and the Cohort 1984 through 1989
National study
Penod 1 (March 1 988-May 1 990)
Period II (June 1 990-November 1991)
Prospective extension (December 1991 -March 1992)
Cohort 1984-1989
Age (yrs)
32
2
1
5
57
2
13
4
50
14
19
37
35
8
5
15
2
2
% Seventy Exposure to FVIII
(FVIII C) (d)
>5 <50
<1 <50
<1 <50
<1 <50
1-5 <50
<1 <50
<1 > 1,000
<1 >250
<1 >1,000
<1 >1,000
<1 > 1,000
<1 > 1,000
<1 > 1,000
<1 >250
<1 >500
<1 >250
<1 <50
<1 <100
Date of Detection
(mon yr)
03-88
01-89
09-89
05-90
12-90
02-91
04-91
06-91
08-91
10-91
10-91
10-91
10-91
10-91
11-91
02-92
04-84
07-85
Max Titer
(BU/mL)
2
7
22
54
pos*
14
222
35
18
3
457
6
11
10
38
15
68
11
All patients hsted in the table had clmical Symptoms of an mhibitor, le, decreased response to Substitution treatment, all but two (one in the national
study and one m the cohort 1984-1989) were detected because of clmical suspicion of an mhibitor The two patients with type B mhibitors m penod
II of the national study, and the 11 patients with type B mhibitors m the cohort 1984-1989 are not hsted m this table
* No mhibitor measurement durmg treatment with over 20,000 IU FVIII/d
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Table 3. Comparison of Type A Inhibitor Incidence
in Dutch and US Cohorts
Table 4. Exposure to Factor VIII CPS and Factor VIII CPS-P in
the National Study
Incidence
(X10"3 patient-years) CI95-
US cohortt
(n = 1,306)§
Cohort 1984-1989
(n = 144)§
National study
Penod l
(March 1988-May 1990)
(n = 411)§
Penod II
(June 1990-November 1991)
(n = 410)§
Prospective extension
(December 1991-Manch 1992)
(n = 210)5
6 2 Φ
3 9
4 4
20 1
166
40-92
05-142
12-113
100-35 9
0 4-92 4
* 95% confidence mterval
t Data from McMillan et al 19
Φ Recalculated from report by McMillan et al '9
§ Patients entering the study penod without an apparent mhibitor
Forty-five of the 48 "ever" type A Inhibitors had severe
hemophilia, l moderately severe, and 2 mild hemophilia. Of
the 27 "current" type A inhibitors, 25 had severe hemophilia
and 2 had mild hemophilia.
The prevalence of "current" type A inhibitor (leaving out
the two type B inhibitors) was 6.0% (27/447, CI95 3.8 to
8.3%), and for "ever" inhibitor it was 10.7% (48/447, CI95
7.9 to 13.6%). For severe hemophilia only, these figures for
"current" inhibitor were 8.6% (25/292), and for "ever" in-
hibitor were 15.4% (45/292).
The incidence of type A inhibitor development (calculated
for those who never had had an inhibitor previously) over
the total period from March 1988 through November 1991
was 10.1/1,000 patient-years (15/1,490 years, CI95 5.6 to
18.3/1,000 patient-years). For period I (March 1988 through
May 1990) the incidence of type A inhibitors was 4.4/1,000
patient-years (4/906 years, CI95 1.2 to 11.3/1,000 patient-
years) and for period II (June 1990 through November 1991)
it was 20.1/1,000 patient-years (l 1/548 years, CI95 10.0 to
35.9/1,000 patient-years) (Table 3). The risk (rate ratio) of
inhibitor development was 4.5 times higher in the second
period than in the first period (CI95 1.4 to 14.3).
When a particular factor is a risk factor for disease, one
generally expects this factor to be more often present among
patients than among nonpatients. Therefore, if a factor VIII
concentrate gave rise to an increased risk of inhibitors, one
would expect that this product was used by a higher propor-
tion of the patients who developed inhibitors äs compared
with those who did not develop an inhibitor. In the first period
(March 1988 through May 1990), 2 of the only 4 patients
who developed an inhibitor had been exposed to Factor VIII
CPS, which appeared not to differ from the proportion ex-
posed among those who did not develop an inhibitor in this
period (Table 4). However, in the second period (June 1990
through November 1991), there was a difference in exposure
to pasteurized Factor VIII CPS-P between inhibitor and non-
inhibitor patients. All 13 patients who developed inhibitors
in this second period had been exposed to Factor VIII CPS-
P, whereas only 75 percent (298 patients) of the 397 patients
Period 1 (March 1 988-May 1 990)*
New inhibitor in this period
No inhibitor m this period
Period II (June 1 990-November 1991)*
New inhibitor m this penodt
No inhibitor m this period
Exposed
(no of patients)
Factor VIII
CPS
2
183
Factor VIII
CPS-P
13
298
Not Exposed
(no of
patients)
No Factor VIII
CPS
2
227
No Factor VIII
CPS-P
0
99
* Only patients without an inhibitor before each penod
t Two type B inhibitors mcluded
who remained without an inhibitor until the end of the study
period had been treated with Factor VIII CPS-P (X2 4.27, P
= .039) (Table 4).
Four of the 11 type A inhibitor patients detected in period
II (June 1990 through November 1991) were over 25 years
old when their inhibitor was discovered, äs compared with
only l of the 4 inhibitor patients found in period I (March
1988 through May 1990). The 11 patients who developed a
type A inhibitor in period II (June 1990 through November
1991) had been heavily exposed to factor VIII products before
inhibitor development in all but 2 cases (over 250 transfusions
in 9, and over 1,000 transfusions in 6). In contrast, the four
patients who developed inhibitors in period I (March 1988
through May 1990) all had received less than 50 infusions
before the inhibitor detection (P = .01) (Table 5).
The second inhibitor test after 3 months of additional fol-
low-up was performed in 210 of 219 patients who had no
inhibitor detected at the first measurement and who had re-
ceived factor VIII products in these 3 months. Among 184
patients who had used Factor VIII CPS-P in the interval,
with a total observation time of 52.5 years, one clinically
Table 5. Exposure Days to Factor VIII Preparations of Type A
Inhibitor Patients in Dutch and US Cohorts
Cumulative Exposure
to FVIII Preparations
<250d
(no of
patients)
>250d
(no of
patients)
US cohort*
(n = 24) 24 0
Cohort 1984-1989
( n = 2 ) 2 0
National study
Period l (March 1988-May 1990)
( n = 4 ) 4 0
Period II (June 1990-November 1991)
(n = 11) 2 9
* Data from McMillan et al 19
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relevant mhibitor (16 BU/mL) was detected (mcidence 19 O/
l ,000 patient-years for patients who were treated with Factor
VIII CPS-P, and 16 6/1,000 patient-years for all 210 patients
m whom a follow-up measurement was performed) This 15-
year-old patient had received well over 250 transfusions m
his lifetime In addition, one transient mhibitor without
Symptoms (maximum titer l 5 BU/mL) was detected m a 2-
year-old patient
Retrospective cohort sludy on mhibitor development The
cohort consisted of 144 patients who had at least two mhibitor
measurements belween 1984 and 1990 One patient, not
known to have an mhibitor, died durmg the study penod of
intracerebral bleedmg, four patients were lost to follow-up
because they moved house These patients are mcluded in
the analysis until the last day of follow-up Information The
general charactenstics of these patients are shown in Table
l
Most patients (102, 71%) had received over 100 mfusions
while under observation, and only nme (6%), less than 10
mfusions Most patients had received treatment with either
cryoprecipitate or Dutch concentrate (mtermediate punty
factor VIII concentrate and its successor factor VIII CPS), or
both
A total number of 527 mhibitor determmations were per-
formed durmg an observation penod of 509 patient-years
Inhibitor titers over l BU/mL were found m 13 patients In
two patients, both aged 2 at first mhibitor detection, mhibitor
activity was shown on multiple occasions, with maximum
levels of 11 and 68 BU/mL Both patients developed bleedmg
Problems, in one patient these were the reason to perform
an mhibitor test These two patients were classified äs type
A Inhibitors (Table 2) In 11 patients we found type B mhib-
itors These were all detected at routme screenmg and were
not associated with climcal problems In nme patients the
mhibitor activity had been shown only once, in one patient
twice m l week, and m one patient once m 1987 (l l BU/
mL) and once m 1989 (l 2 BU/mL), with subsequent negative
tests in all 11 patients Inhibitor titers for these type B inhib-
itors ranged from l l to 2 4 BU/mL, the ages of these patients
ranged from 10 to 48 years Therefore, from this cohort we
estimate an mcidence of type A Inhibitors of 3 9/1,000 pa-
tient-years (2/509 years, CI95 0 5 to 14 2/1,000 patient-years)
(Table 3) and an mcidence of type B Inhibitors of 21 6/1,000
patient-years (l 1/509 years, CI95 10 8 to 38 7/1,000 patient-
years)
DISCUSSION
Smce June 1990, we have observed an mcreased mcidence
of mhibitor development among hemophiha A patients in
The Netherlands, particularly among patients who had re-
ceived numerous mfusions with factor VIII preparations This
mcreased mcidence is hkely to be associated with the usage
of a recently introduced pasteunzed factor VIII concentrate
Although mhibitor development is not uncommon in pre-
viously untreated patients (pups), it is rare m multitransfused
patients McMillan et al19 found an mcidence of 8/1,000 pa-
tient-years m a cohort of previously treated patients (6 2/
1,000 patient-years for type A Inhibitors), which is much
lowerthan the mcidence of 20 1/1,000 patient-years we found
smce June 1990 It is important to note that even though
mhibitors were detected among older patients in McMillan
et al's study, all of these mhibitor patients had received less
than 250 mfusions m their lifetime (Table 3)
Durmg penod I (March 1988 through May 1990), before
the introduction of Factor VIII CPS-P, äs well äs in the re-
trospective cohort observed from 1984 through 1990, we
found mcidence rates of new mhibitor development that were
similar to the US figures 4 4/1,000 patient-years m penod I
(March 1988 through May 1990) and 3 9/1,000 patient-years
m the cohort followed from 1984 through 1989 (Table 3)
All combmed, the mcreased mcidence after the introduction
of a new factor VIII concentrate, the occurrence of mhibitors
in multitransfused patients, the exposure to this product in
all mhibitor patients, äs well äs the mdependent reports from
Belgium, render an association with the product more than
hkely
In a study hke this, in which mhibitors were actively sought
after, there may be overestimation because of detection bias,
le, positive test results in patients who would otherwise not
have been tested, or have been tested later We have tried to
minimize this possibihty of bias by focusing on type A m-
hibitors, whose climcal Symptoms were sufficiently severe to
ensure detection also m the absence of a study hke this Nev-
ertheless, äs the dates of first detection show (Table 2), some
detection bias may have been present, and therefore our m-
cidence estimates may have been shghtly mflated
Among the 144 patients of the cohort 1984 through 1989,
we found a high mcidence of type B mhibitors (22/1,000
patient-years, äs compared with approximately 2/1,000 pa-
tient-years in the US cohort19) The relevance of this obser-
vation is uncertam, and we feel that assay vanability cannot
be ruled out äs an explanation 34 In this respect, it has to be
borne m mind that these tests were performed in a routme
climcal fashion, and no attempts were undertaken to confirm
low-titered mhibitors that appeared without climcal impor-
tance
To our knowledge, this is the first mstance m which m-
hibitor development has been associated with the use of a
particular factor VIII product m multitransfused patients who
switched from one product to another This may be related
to an altered epitopic structure of the factor VIII molecule
m pasteunzed Factor VIII CPS Because this factor VIII con-
centrate has not been used outside The Netherlands and Bel-
gium, the absolute number of patients who developed mhib-
itors remamed limited, which would not have been the case
if the product had been used m larger populations We believe
that to avoid future and possibly larger epidemics of mhib-
itors, physicians who treat hemophiha patients should per-
form mhibitor tests at regulär mtervals, especially when their
patients change from one clottmg factor preparation to an-
other
APPENDIX
Participatmg centers (9) were Van Creveldklimek, Bilthoven (Dr
H M van den Berg, Dr G Roosendaal, and Dr E P Mauser-Bun-
schotcn), Academic Medical Center, Amsterdam (Dr H Heijboer
and Dr M Peters), Umversity Hospital Leiden (Dr E Briet, Dr F R
Rosendaal, Dr E T van't Veer Korthof, and Dr M H van Weel-
Sipman), Umversity Hospital Groningen (Dr J van der Meer and
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Dr J K M van Loon), Umversity Hospital Rotterdam (Dr J Stibbe
a n d D r J J Michiels), Radboudziekenhuis Nijmegen (Dr I R O No-
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